secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001746473-24-000073
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics Q1 net loss $47.0M; bexotegrast adaptive Phase 2b/3 accelerated
--------------------------------------------------------------------------------

- Net loss $47.0M in Q1 2024 vs $37.5M in Q1 2023; R&D expenses rose to $37.1M from $29.3M.
- BEACON-IPF Phase 2b/3 adaptive design upsized to 360 patients; enrollment completion expected Q1 2025.
- Phase 2a PET imaging trial completed; topline data on total lung collagen and FVC expected in weeks.
- Oxford loan facility upsized by $50M to $150M; $30M drawn. Cash $483.9M funded through 2026.
- Regulatory clearance for PLN-101325 Phase 1 in muscular dystrophy; Phase 1 of PLN-101095 in solid tumors ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647324000073/0001746473-24-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647324000073/plrx-20240506.htm
  HTML page:      https://secwatch.observer/filing/0001746473-24-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer